BUZZ-Gilead Sciences Inc: Sovaldi sales slip
** U.S. drugmaker's shares down about 4 pct at $110.70 in extended trading
** Sales of $84,000 hepatitis C drug Sovaldi dipped as doctors and patients awaited a recently approved combination pill
** Q3 Sovaldi sales $2.8 billion, below the average Wall Street estimate of $2.97 billion, according to Deutsche Bank
** Up to Monday's close, Gilead shares had gained about 51 pct this year
© Thomson Reuters 2017 All rights reserved.